Literature DB >> 35459220

Multifocal lumbar myxopapillary ependymoma presenting with drop metastasis: a case report and review of the literature.

Joanna K Tabor1,2, Brendan Ryu2,3, Daniel Schneider2, Daniel M Sciubba2, Ashwatha Narayana4, Avraham Zlochower5, Randy S D' Amico6.   

Abstract

INTRODUCTION: Spinal myxopapillary ependymomas (SME) are rare WHO grade II neoplasms of the spinal cord. Despite their good prognosis, they have a high propensity for metastasis and recurrence, although the presentation of SME as multifocal is uncommon. CASE
PRESENTATION: Here we describe a rare case of a 34-year-old man who presented with painful bilateral radiculopathy with sexual dysfunction and altered sensation with defecation. The patient also reported worsening weakness of bilateral lower extremities when climbing stairs. Biopsy results revealed multifocal SME in the lumbar and sacral spine that was treated with staged surgical resection and post-operative focal radiation therapy. DISCUSSION: We discuss and evaluate surgical resection and the role of postoperative radiotherapy for SME. We also review the literature surrounding multifocal SME presenting in adults.
© 2022. The Author(s), under exclusive licence to International Spinal Cord Society.

Entities:  

Mesh:

Year:  2022        PMID: 35459220      PMCID: PMC9033832          DOI: 10.1038/s41394-022-00513-x

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  31 in total

1.  Disseminated adult spinal extramedullary myxopapillary ependymoma.

Authors:  Zafer Orkun Toktaş; Mustafa Kemal Demir; Özlem Yapıcıer; Akın Akakın; Baran Yılmaz; Deniz Konya
Journal:  Spine J       Date:  2015-08-04       Impact factor: 4.166

Review 2.  Disseminated spinal myxopapillary ependymoma in an adult at initial presentation: a case report and review of the literature.

Authors:  David Straus; Lee A Tan; Ippei Takagi; John E O'Toole
Journal:  Br J Neurosurg       Date:  2014-01-24       Impact factor: 1.596

Review 3.  Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review.

Authors:  Yasushi Fujiwara; Hideki Manabe; Bunichiro Izumi; Takayuki Shima; Nobuo Adachi
Journal:  Eur Spine J       Date:  2017-12-21       Impact factor: 3.134

4.  Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas.

Authors:  Tie Liu; Chenlong Yang; Xiaofeng Deng; Anqi Li; Yu Xin; Jun Yang; Yulun Xu
Journal:  Neurosurg Rev       Date:  2019-08-31       Impact factor: 3.042

5.  Myxopapillary ependymoma. A clinicopathologic and immunocytochemical study of 77 cases.

Authors:  P R Sonneland; B W Scheithauer; B M Onofrio
Journal:  Cancer       Date:  1985-08-15       Impact factor: 6.860

Review 6.  Ependymoma.

Authors:  Michele Reni; Gemma Gatta; Elena Mazza; Charles Vecht
Journal:  Crit Rev Oncol Hematol       Date:  2007-05-04       Impact factor: 6.312

Review 7.  Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review.

Authors:  William B Feldman; Aaron J Clark; Michael Safaee; Christopher P Ames; Andrew T Parsa
Journal:  J Neurosurg Spine       Date:  2013-08-23

Review 8.  MYXOPAPILLARY EPENDYMOMA OF THE SPINAL CORD IN ADULTS: A REPORT OF PERSONAL SERIES AND REVIEW OF LITERATURE.

Authors:  Ibrahim Omerhodžić; Mirza Pojskić; Krešimir Rotim; Bruno Splavski; Lukas Rasulić; Kenan I Arnautovic
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780

9.  Multicentric extramedullary myxopapillary ependymomas: Two case reports and literature review.

Authors:  Federico Landriel; Pablo Ajler; Nicolas Tedesco; Damián Bendersky; Eduardo Vecchi
Journal:  Surg Neurol Int       Date:  2012-09-13

10.  Spinal drop metastasis in myxopapillary ependymoma: a case report and a review of treatment options.

Authors:  James E Bates; Carl R Peterson; Gabrielle A Yeaney; Kevin A Walter; Thomas Lundquist; Douglas Rosenzweig; Michael T Milano
Journal:  Rare Tumors       Date:  2014-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.